Pdt Partners, LLC Immuno Gen, Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $2.15 Million - $3.48 Million	-330,700 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $65,120 - $134,816	-17,600 Reduced 5.05%	330,700 $2.13 Million
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $233,728 - $375,936	-70,400 Reduced 16.81%	348,300 $1.6 Million
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $512,766 - $1.64 Million	241,871 Added 136.78%	418,700 $1.43 Million
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $397,865 - $1.03 Million	176,829 New	176,829 $903,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.